Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus · 4d ago
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients
Business Wire · 5d ago
BRIEF-ImmunityBio Announces 78% Complete Response Following Chemotherapy-Free Treatment For Lymphoma Patients · 5d ago
ImmunityBio posts results from early-stage blood cancer study
ImmunityBio (IBRX) announces results from its Phase 1 study evaluating Anktiva (N-803), its IL-15 superagonist, in combination with Rituxan (rituximab) in certain patients with indolent non-Hodgkin lymphoma, a rare form of
Seekingalpha · 5d ago
BRIEF-ImmunityBio Says May Offer, Sell Shares Having Offering Price Of Up To $500 Million · 6d ago
Immunitybio Files for Mixed-Securities Shelf Offering
MT Newswires · 6d ago
BRIEF-ImmunityBio Announces Launch Of Phase 2 Trial Of IL-15 Superagonist Anktiva With Antiretroviral Therapy · 04/29 13:12
ImmunityBio reports launch of Phase 2 trial of Anktiva with ART to inhibit HIV reservoirs
The U.S. Military HIV Research Program has launched a Phase 2 clinical trial in Thailand to evaluate ImmunityBio’s (IBRX) interleukin-15 (IL-15) superagonist Anktiva (also called N-803) in combination with antiretroviral
Seekingalpha · 04/29 13:11
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that the U.S. Military HIV Research Program (MHRP) at the Walter...
BusinessWire - BZX · 04/29 13:04
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/27 20:57
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has administered its proprietary Natural Killer cells to more...
BusinessWire - BZX · 04/22 13:00
ImmunityBio Reaches Dosing Milestone in Natural Killer Cell Trials
MT Newswires · 04/22 11:07
RIOT, MVIS, MSRT and FOLD among premarket gainers
Galectin Therapeutics (GALT) +27% as its belapectin + Keytruda enhances tumor response in melanoma, head/neck cancer.Bit Digital (BTBT) +17%.UTStarcom Holdings (UTSI) +14%.Greenwich LifeSciences (GLSI) +15% after update on GP2 phase III clinical
Seekingalpha · 04/14 12:22
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data · 04/09 20:18
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? · 04/09 10:20
Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses
Benzinga · 04/08 14:59
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today reported initial data indicating that a single subcutaneous injection of the company’s COVID-19 vaccine candidate in healthy Phase 1 clinical study participants stimulates the ...
Business Wire · 04/08 14:00
ImmunityBio posts early-stage interim data showing potential of COVID-19 vaccine
Announcing preliminary Phase 1 data, ImmunityBio (IBRX) has highlighted the potential of its experimental dual antigen hAd5 S + N vaccine against COVID-19 to provide long-term protection as well as immunity against
Seekingalpha · 04/08 13:39
DJ ImmunityBio Sees Positive Results From Trial of Covid-19 Vaccine Candidate
Dow Jones · 04/08 13:24
ImmunityBio Announces Data Showing Its COVID-19 Vaccine Candidate Induced A 10-Fold Increase In T Cell Response Equivalent To T Cell Responses From Patients Previously Infected With SARS-CoV-2
Preliminary Phase 1b findings in participants receiving the dual antigen hAd5 S + N vaccine generated Th1 dominant S and N specific T cells after a single prime subcutaneous injection The magnitude of this T cell
Benzinga · 04/08 13:02
Webull provides a variety of real-time IBRX stock news. You can receive the latest news about ImmunityBio Inc through multiple platforms. This information may help you make smarter investment decisions.
About IBRX
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term immunological memory. The Company is engaged in developing molecular and product platforms based on three key modalities: activating NK and T cells using antibody cytokine fusion proteins, activating tumoricidal macrophages using low-dose synthetic immunomodulators, and generating memory T cells using vaccine candidates developed with second-generation adenovirus (hAd5) technology. It is also developing therapies, including vaccines, for the prevention and treatment of human immunodeficiency virus (HIV), influenza, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its human adenovirus (hAd5) vaccine technologies.